Latest Research Report Overview on the US Stock AI Sector: Storage/Memory Remains the Strongest Theme, Institutional Target Prices Raised Across the Board
BlockBeats News, June 2nd. Over the weekend until today, several investment banks released AI infrastructure research reports, breaking down AI computing power expansion into a "second-order bottleneck," with Storage/Memory> SSD Controller> Data Center Power/Liquid Cooling> GPU/Cloud Platform> MLCC> AI Security. AI data centers have extended their reach from GPUs to backend storage, power supply, and cooling, with the supply-demand imbalance driving institutions to significantly raise their target prices and ratings for related assets. This aligns closely with the trillion-dollar market cap achievements of memory giants last week (MU, SK Hynix) and the strong performance of tech stocks in after-hours trading. Below are the highlights of the institutional research reports:
SNDK (SanDisk): Susquehanna, GF Securities rated as Positive/Buy with target prices as high as $3,250 and $1,277, respectively. The reason is the severe imbalance in NAND and enterprise SSD supply and demand, with continuous upward revisions in storage demand from cloud providers for AI.
MU (Micron): Raymond James, in its latest update on June 1st, raised the target price significantly from $530 to $1,100, maintaining an Outperform rating; Seeking Alpha article also bullish. Strong AI memory demand, HBM/DRAM price hikes + capacity expansion. MU has approached the $1,000 mark and surpassed a trillion-dollar market cap, in complete alignment with the research report's logic.
SIMO (Silicon Motion): BofA maintains a Buy rating, raising the target price from $320 to $450. Enterprise SSD sales exceeding expectations, with AI storage capital expenditures driving NAND controller demand.
NVDA (Nvidia): Goldman Sachs and multiple Seeking Alpha reports maintain a Buy rating, with a target price of $285, optimistic about Vera Rubin, CPU, network, and software full-stack AI platform.
AMZN (Amazon): Truist Buy, raising the target price from $310 to $320, with AWS+Anthropic/OpenAI workloads and Trainium3/4 accelerators gaining traction.
VST (Vistra): Jefferies/Morgan Stanley Buy, bullish on electricity demand, with a target price around $212.
ECL (Ecolab): UBS/BofA Buy, target price $325-$345, liquid cooling, water treatment demand surging due to increased computing power density.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
